---
title: NorthEast BioLab vs WuXi AppTec
slug_a: nebiolab
slug_b: wuxiapptec
site: cro
review_signal_gate: closed
canonical_path: /compare/nebiolab/wuxiapptec
---

# NorthEast BioLab vs WuXi AppTec

Side-by-side profile data from each company listing on this directory.

## NorthEast BioLab

- Profile: [/companies/nebiolab](/companies/nebiolab)

NorthEast BioLab — Bioanalytical CRO providing PK/PD, immunogenicity (ADA/nAb), cytokine, and biomarker assays across LC-MS, Meso Scale Discovery, ELISA, and ddPCR platforms. Operates GLP/GCLP-compliant facilities and reports DEA and CT approval for Schedule I–IV bioanalysis.

Services: 13. Modalities: 6. Indications: 0. Locations: 0. Certifications: 0. The strongest documented coverage currently appears in services (13).

### Services

- In Vitro ADME / DMPK
- Preclinical In Vivo Studies
- In Vivo PK / PD Studies
- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Immunogenicity Assays (ADA / NAb)
- Biomarker Assays
- Flow Cytometry Services
- Clinical Trial Services
- Central Laboratory Services
- Analytical Method Development & Validation
- ICH Stability Studies

### Modalities

- Small Molecule
- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- Cell Therapy
- Gene Therapy
- Vaccine

### Indications

- Data not yet provided.

### Phases

- Discovery
- Preclinical (General)
- Phase I
- Phase II
- Phase III
- Phase IV

### Sourcing models

- Data not yet provided.

## WuXi AppTec

- Profile: [/companies/wuxiapptec](/companies/wuxiapptec)

WuXi AppTec — Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.

Services: 41. Modalities: 10. Indications: 14. Locations: 2. Certifications: 0. The strongest documented coverage currently appears in services (41).

### Services

- Discovery Research
- Target Identification & Validation
- High-Throughput Screening
- Medicinal Chemistry
- Computational & In-Silico Drug Discovery
- Protein Engineering
- Preclinical In Vitro Studies
- In Vitro Pharmacology
- In Vitro ADME / DMPK
- Safety Pharmacology
- Genetic Toxicology
- Preclinical In Vivo Studies
- In Vivo Efficacy Models
- In Vivo PK / PD Studies
- GLP Toxicology
- Carcinogenicity Studies
- DART (Reproductive & Developmental Toxicology)
- Specialized & Large-Animal Models
- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Immunogenicity Assays (ADA / NAb)
- Biomarker Assays
- Flow Cytometry Services
- Clinical Trial Services
- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Phase IV / Post-Marketing
- Data Management & eClinical
- Biostatistics & Statistical Programming
- Pharmacovigilance & Drug Safety
- Medical Writing
- Regulatory Affairs
- US FDA Regulatory Strategy
- EU EMA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- China NMPA Regulatory Strategy
- Analytical Method Development & Validation
- ICH Stability Studies
- Translational Research

### Modalities

- Small Molecule
- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- Antibody-Drug Conjugate (ADC)
- Oligonucleotide
- mRNA
- Cell Therapy
- Gene Therapy
- Peptide
- Vaccine

### Indications

- Oncology
- Immunology
- Neurology
- Psychiatry
- Metabolic
- Cardiovascular
- Infectious Disease
- Rare Disease
- Respiratory
- Dermatology
- Ophthalmology
- Gastroenterology
- Nephrology
- Women's Health

### Phases

- Discovery
- Preclinical (General)
- Preclinical (IND-Enabling)
- Phase I
- Phase II
- Phase III
- Phase IV

### Sourcing models

- Full-Service Outsourcing (FSO)